KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) has announced the presentation of novel data on long-term prophylaxis (LTP) and sebetralstat at the Western Society of Allergy, Asthma & Immunology (WSAAI) 2025 Annual…
Bristol Myers Squibb (NYSE: BMY) has announced positive topline results from the Phase 2 TRANSCEND FL trial, evaluating Breyanzi® (lisocabtagene maraleucel) in adult patients with relapsed or refractory indolent B-cell…
Nutriband Secures U.S. Patent Approval for Aversa™ Transdermal Abuse Deterrent Technology Nutriband a pharmaceutical company specializing in the development of prescription transdermal products, recently announced that it has received a…
Kidney Transplant Eledon Pharmaceuticals Advances Xenotransplantation with Tegoprubart Kidney Transplant Eledon Pharmaceuticals has announced that its investigational anti-CD40L antibody, tegoprubart, was a crucial component of the immunosuppression regimen used in…
Levi & Korsinsky, LLP Announces Securities Fraud Lawsuit Against Regeneron Pharmaceuticals, Inc. Levi & Korsinsky, LLP has issued a notice to investors in Regeneron Pharmaceuticals the regarding a class action…
Protein Prediction LG Develops Next-Generation AI for Protein Structure Prediction to Revolutionize Drug Discovery On February 5th, LG AI Research took a significant step in advancing the field of artificial…
TheraSyn Bio & Rubix LS Launch Project Panacea A Revolutionary Topical Breast Cancer Treatment Breast cancer remains one of the most prevalent and life-altering diseases affecting millions worldwide. Traditional treatment…
Sangamo Reports Updated Phase 1/2 STAAR Data for Fabry Disease Fabry Disease Sangamo Therapeutics a genomic medicine company, has announced updated results from the Phase 1/2 STAAR study evaluating isaralgagene…
Antibodies.com and Cactus Communications Partner to Accelerate Life Science Manuscript Publication Antibodies.com, a leading provider of high-quality biological reagents for life science researchers, has announced a strategic partnership with Cactus…
Broken String Biosciences Unveils Catalyst Program to Accelerate Gene Editing Therapy Development Broken String Biosciences a leader in advancing gene editing safety, has officially launched its Catalyst Early Access Program…
Merck Begins Phase 3 Trial of Zilovertamab Vedotin for DLBCL Treatment DLBCL Treatment Merck known as MSD outside the United States and Canada, has officially announced the initiation of waveLINE-010,…
Know Labs Technology Licensing (KTL) Announces Official Client Partnership Know Labs is pleased to announce the official launch of its structured client engagement process for Know Labs Technology Licensing (KTL),…
